Moderna, Inc. Lines of Credit, Fair Value Disclosure
Moderna, Inc. (MRNA) had Lines of Credit, Fair Value Disclosure of $12.00 million as of 2021-12-31, per its 10-K filed 2022-02-25.
Discontinued › Notes
us-gaap:LinesOfCreditFairValueDisclosure · last filed 2022-02-25
- 2021-12-31: Lines of Credit, Fair Value Disclosure $12.00M.
- 2020-12-31: Lines of Credit, Fair Value Disclosure $12.00M.
| Period end | Lines of Credit, Fair Value Disclosure |
|---|---|
| 2021-12-31 | $12.00M 10-K · filed 2022-02-25 |
| 2020-12-31 | $12.00M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |